Show simple item record

hal.structure.identifierCentre de Référence Déficits Immunitaires Héréditaires [CEREDIH]
dc.contributor.authorBeauté, J.*
hal.structure.identifierLaboratoire d'Economie de Dauphine [LEDa]
hal.structure.identifierLaboratoire d'Economie et de Gestion des Organisations de Santé [Legos]
dc.contributor.authorLévy, Pierre
HAL ID: 10931
*
hal.structure.identifier
dc.contributor.authorMillet, V.*
hal.structure.identifier
dc.contributor.authorDebré, M.*
hal.structure.identifierCentre de Référence Déficits Immunitaires Héréditaires [CEREDIH]
dc.contributor.authorDudoit, Y.*
hal.structure.identifierCentre de Référence Déficits Immunitaires Héréditaires [CEREDIH]
dc.contributor.authorLe Mignot, L.*
hal.structure.identifier
dc.contributor.authorTajahmady, A.*
hal.structure.identifier
dc.contributor.authorThomas, C.
HAL ID: 12416
*
hal.structure.identifierCentre de Référence Déficits Immunitaires Héréditaires [CEREDIH]
dc.contributor.authorSuarez, F.
HAL ID: 13502
*
hal.structure.identifier
dc.contributor.authorPellier, I.*
hal.structure.identifierCentre de Référence Déficits Immunitaires Héréditaires [CEREDIH]
dc.contributor.authorHermine, O.*
hal.structure.identifier
dc.contributor.authorAladjidi, N.*
hal.structure.identifierCentre de Référence Déficits Immunitaires Héréditaires [CEREDIH]
dc.contributor.authorMahlaoui, N.*
hal.structure.identifierCentre de Référence Déficits Immunitaires Héréditaires [CEREDIH]
dc.contributor.authorFischer, A.
HAL ID: 21112
*
dc.date.accessioned2013-11-08T11:06:49Z
dc.date.available2013-11-08T11:06:49Z
dc.date.issued2010
dc.identifier.issn0009-9104
dc.identifier.urihttps://basepub.dauphine.fr/handle/123456789/12011
dc.language.isoenen
dc.subjectEvaluation
dc.subjectMedical economics
dc.subjectCost of Medical care
dc.subjectHealth Insurance
dc.subjectMedical care
dc.subject.ddc334en
dc.subject.classificationjelI.I1.I12en
dc.subject.classificationjelI.I1.I11en
dc.titleEconomic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies
dc.typeArticle accepté pour publication ou publié
dc.contributor.editoruniversityotherUnité d'Immuno-Hématologie Pédiatrique, CHU Angers, Bordeaux;France
dc.contributor.editoruniversityotherUniversité Paris Descartes, Paris;France
dc.contributor.editoruniversityotherUnité d'Immunologie et d'Hématologie Pédiatrique, Hôpital Necker-Enfants Malades, AP-HP, Paris
dc.contributor.editoruniversityotherCentre de Référence Déficits Immunitaires Héréditaires, Hôpital Necker-Enfants Malades, AP-HP, Paris
dc.contributor.editoruniversityotherMission nationale d'expertise et d'audit hospitaliers, Paris
dc.contributor.editoruniversityotherService d'Hématologie Oncologie Pédiatrique, Hôpital Mère-Enfants, Nantes
dc.contributor.editoruniversityotherUniversité Paris Descartes
dc.contributor.editoruniversityotherUnité d'Immuno-Hématologie Pédiatrique, CHU Angers
dc.description.abstractenLifelong immunoglobulin replacement is the standard, expensive therapy for severe primary antibody deficiencies. This treatment can be administrated either by intravenous immunoglobulin (IVIG) or subcutaneous infusions (SCIG) and delivered at home or in an out-patient setting. This study aims to determine whether SCIG is cost-effective compared with IVIG from a French social insurance perspective. Because both methods of administration provide similar efficacies, a cost-minimization analysis was performed. First, costs were calculated through a simulation testing different hypothesis on costs drivers. Secondly, costs were estimated on the basis of field data collected by a questionnaire completed by a population of patients suffering from agammaglobulinaemia and hyper-immunoglobulin (Ig)M syndrome. Patients' satisfaction was also documented. Results of the simulation showed that direct medical costs ranged from €19 484 for home-based IVIG to €25 583 for hospital-based IVIG, with home-based SCIG in between at €24 952 per year. Estimations made from field data were found to be different, with significantly higher costs for IVIG. This result was explained mainly by a higher immunoglobulin mean dose prescribed for IVIG. While the theoretical model showed very little difference between SCIG and hospital-based IVIG costs, SCIG appears to be 25% less expensive with field data because of lower doses used in SCIG patients. The reality of the dose difference between both routes of administration needs to be confirmed by further and more specific studies.
dc.relation.isversionofjnlnameClinical and Experimental Immunology
dc.relation.isversionofjnlvol160
dc.relation.isversionofjnlissue2
dc.relation.isversionofjnldate2010
dc.relation.isversionofjnlpages240-245
dc.relation.isversionofdoi10.1111/j.1365-2249.2009.04079.x
dc.contributor.countryeditoruniversityotherFRANCE
dc.relation.isversionofjnlpublisherBlackwell Scientific Publications Ltd
dc.subject.ddclabelEconomie socialeen
dc.relation.forthcomingnonen
dc.relation.forthcomingprintnonen
dc.description.ssrncandidatenon
dc.description.halcandidateoui
dc.description.readershiprecherche
dc.description.audienceInternational
dc.relation.Isversionofjnlpeerreviewedoui
dc.date.updated2016-03-25T11:49:41Z
hal.identifierhal-01293729*
hal.version1*
hal.update.actionupdateMetadata*
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record